Tartaric acid
Identification
- Name
- L-tartaric acid
Commonly known or available as Tartaric acid - Accession Number
- DB09459
- Description
Tartaric acid is a white crystalline organic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics, and is a dihydroxyl derivative of succinic acid.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for L-tartaric acid (DB09459)
- Weight
- Average: 150.0868
Monoisotopic: 150.016437924 - Chemical Formula
- C4H6O6
- Synonyms
- (+)-(R,R)-tartaric acid
- (+)-L-tartaric acid
- (+)-Tartaric acid
- (+)-Weinsäure
- (2R,3R)-2,3-Dihydroxybernsteinsäure
- (2R,3R)-2,3-dihydroxysuccinic acid
- (2R,3R)-Tartaric acid
- (R,R)-(+)-tartaric acid
- (R,R)-Tartaric acid
- ácido tartárico
- L-threaric acid
- Rechtsweinsäure
- Tartaric acid
- Weinsteinsäure
- External IDs
- E 334
- E-334
- FEMA NO. 3044
- INS NO.334
- INS-334
- NSC-62778
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
Tartaric Acid is primarily indicated in conditions like Antiscorbutic, Antiseptic.
- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Tartaric acid is used to generate carbon dioxide through interaction with sodium bicarbonate following oral administration. Carbon dioxide extends the stomach and provides a negative contrast medium during double contrast radiography. In high doses, this agent acts as a muscle toxin by inhibiting the production of malic acid, which could cause paralysis and maybe death.
- Mechanism of action
- Not Available
- Absorption
Oral or parenteral doses of monosodium 14C-L(+)-tartrate (400 mg/kg) are rapidly excreted by rats and a proportion completely metabolized to CO2. The oral dose was well-absorbed.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Most tartarate that is consumed by humans is metabolized by bacteria in the gastrointestinal tract , primarily in the large instestine.
- Route of elimination
Only about 15-20% of consumed tartaric acid is secreted in the urine unchanged.
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Routes of Entry: Inhalation. Ingestion.
Toxicity to Animals: Lowest Published Lethal Dose: LDL [Rat - Route: oral; Dose: 7500 mg/kg LDL Rabbit - Route: Oral; Dose: 5000 mg/kg LDL [Dog] - Rout: Oral; Dose: 5000 mg/kg Lethal Dose/Conc 50% kill: LD50 [Mouse] - Route: Intravenous; Dose: 485 mg/kg
Other Toxic Effects on Humans: Acute Potential Health Effects: Skin: Causes skin irritation Eyes: Causes eye irritation Inhalation: Causes respiratory tract irritation Ingestion: Causes gastrointestinal tract irritation with nausea, vomiting and diarrhea. May affect kidneys (kidney damage), blood, and behavior (convulsions, somnolence), and respiration. Chronic Potential Health Effects: Ingestion: Repeated or prolonged ingestion may cause lesions of the mouth, gastric ulcers, gastrointestinal hyperacidity, and symptoms similar to those of metal fume fever - flu-like condition with fever, chills, sweats, nausea, vomiting, muscle aches, pains, and weakness. Skin: Repeated or prolonged skin contact may cause skin ulcerations or lesions.
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmphetamine The excretion of Amphetamine can be decreased when combined with L-tartaric acid. Benzphetamine The excretion of Benzphetamine can be decreased when combined with L-tartaric acid. Demeclocycline The therapeutic efficacy of Demeclocycline can be decreased when used in combination with L-tartaric acid. Dextroamphetamine The excretion of Dextroamphetamine can be decreased when combined with L-tartaric acid. Diethylpropion The excretion of Diethylpropion can be decreased when combined with L-tartaric acid. Doxycycline The therapeutic efficacy of Doxycycline can be decreased when used in combination with L-tartaric acid. Eravacycline The therapeutic efficacy of Eravacycline can be decreased when used in combination with L-tartaric acid. Iofetamine I-123 The excretion of Iofetamine I-123 can be decreased when combined with L-tartaric acid. Lisdexamfetamine The excretion of Lisdexamfetamine can be decreased when combined with L-tartaric acid. Lymecycline The therapeutic efficacy of Lymecycline can be decreased when used in combination with L-tartaric acid. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AVORAL EFFERVESCENT GRANULES L-tartaric acid (0.89 g) + Citric acid (0.72 g) + Sodium bicarbonate (1.76 g) + Sodium citrate (0.63 g) Granule, for solution Oral XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD 2020-09-08 Not applicable Malaysia 
Avosoda Effervescent Granules L-tartaric acid (0.89 g) + Citric acid (0.72 g) + Sodium bicarbonate (1.76 g) + Sodium citrate (0.63 g) Granule, for solution Oral Abio Marketing Sdn Bhd 2020-09-08 Not applicable Malaysia Baros Effervescent Granules L-tartaric acid (420 mg) + Sodium bicarbonate (460 mg) Granule, effervescent Oral Tyco Healthcare 1988-12-31 2010-01-07 Canada 
Bicaruvas L-tartaric acid (2 g/944mL) + Calcium carbonate (1 g/944mL) + Citric acid monohydrate (15 g/944mL) + Sodium bicarbonate (19 g/944mL) Powder, for solution Oral Prosana Distribuciones, S.A. De C.V. 2013-04-23 Not applicable US 
Bicaruvas L-tartaric acid (220 mg/118mL) + Calcium carbonate (50 mg/118mL) + Citric acid monohydrate (1827 mg/118mL) + Sodium bicarbonate (2452 mg/118mL) Powder, for solution Oral Prosana Distribuciones, S.A. De C.V. 2013-04-23 Not applicable US Bicaruvas L-tartaric acid (2 g/944mL) + Calcium carbonate (1 g/944mL) + Citric acid monohydrate (15 g/944mL) + Sodium bicarbonate (19 g/944mL) Powder, for solution Oral Prosana Distribuciones, S.A. De C.V. 2013-04-23 Not applicable US Brioschi Childrens Effervescent Antacid L-tartaric acid (1.05 g/4g) + Sodium bicarbonate (1.17 g/4g) Granule, effervescent Oral Brioschi, Inc. 2011-04-27 2016-03-25 US Brioschi Effervescent Antacid L-tartaric acid (1.63 g/6g) + Sodium bicarbonate (1.8 g/6g) Granule, effervescent Oral Brioschi, Inc. 2010-09-20 2016-03-25 US CLEAROGOUT ALKALINISING EFFERVESCENT GRANULES L-tartaric acid (0.89 g) + Citric acid (0.72 g) + Sodium bicarbonate (1.76 g) + Sodium citrate (0.63 g) Granule, for solution Oral PAHANG PHARMACY SDN. BHD. 2020-09-08 Not applicable Malaysia E-Z-gas 2 Granules L-tartaric acid (1.648 g) + Sodium bicarbonate (1.808 g) Powder Oral Therapex Division De E Z Em Canada Inc 1985-12-31 2000-04-13 Canada
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as sugar acids and derivatives. These are compounds containing a saccharide unit which bears a carboxylic acid group.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Sugar acids and derivatives
- Alternative Parents
- Short-chain hydroxy acids and derivatives / Beta hydroxy acids and derivatives / Monosaccharides / Fatty acids and conjugates / Dicarboxylic acids and derivatives / Alpha hydroxy acids and derivatives / Secondary alcohols / 1,2-diols / Carboxylic acids / Organic oxides show 2 more
- Substituents
- 1,2-diol / Alcohol / Aliphatic acyclic compound / Alpha-hydroxy acid / Beta-hydroxy acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Dicarboxylic acid or derivatives / Fatty acid show 7 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- tartaric acid (CHEBI:15671)
Chemical Identifiers
- UNII
- 4J4Z8788N8
- CAS number
- 87-69-4
- InChI Key
- FEWJPZIEWOKRBE-JCYAYHJZSA-N
- InChI
- InChI=1S/C4H6O6/c5-1(3(7)8)2(6)4(9)10/h1-2,5-6H,(H,7,8)(H,9,10)/t1-,2-/m1/s1
- IUPAC Name
- (2R,3R)-2,3-dihydroxybutanedioic acid
- SMILES
- O[C@H]([C@@H](O)C(O)=O)C(O)=O
References
- General References
- Chasseaud LF, Down WH, Kirkpatrick D: Absorption and biotransformation of L(+)-tartaric acid in rats. Experientia. 1977 Aug 15;33(8):998-9. [PubMed:891842]
- Pubchem [Link]
- External Links
- Human Metabolome Database
- HMDB00956
- PubChem Compound
- 444305
- PubChem Substance
- 347827854
- ChemSpider
- 392277
- 37578
- ChEBI
- 15671
- ChEMBL
- CHEMBL1236315
- ZINC
- ZINC000000895301
- PDBe Ligand
- TLA
- Wikipedia
- Tartaric_acid
- PDB Entries
- 1alu / 1d5r / 1d6j / 1ei6 / 1eks / 1fs5 / 1gu1 / 1h3d / 1j2z / 1k2y … show 459 more
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Healthy Volunteers 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder, for solution Oral Granule, effervescent Oral Powder Oral Solution Oral Tablet Oral Granule, for solution Oral Powder - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 161.0 mg/mL ALOGPS logP -1.3 ALOGPS logP -1.8 ChemAxon logS 0.03 ALOGPS pKa (Strongest Acidic) 2.72 ChemAxon pKa (Strongest Basic) -4.3 ChemAxon Physiological Charge -2 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 115.06 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 26.21 m3·mol-1 ChemAxon Polarizability 11.33 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Catalytic activity
- General Function
- Udp-galactose:beta-n-acetylglucosamine beta-1,3-galactosyltransferase activity
- Specific Function
- Involved in the biosynthesis of L2/HNK-1 carbohydrate epitope on glycoproteins. Can also play a role in glycosaminoglycan biosynthesis. Substrates include asialo-orosomucoid (ASOR), asialo-fetuin, ...
- Gene Name
- B3GAT1
- Uniprot ID
- Q9P2W7
- Uniprot Name
- Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1
- Molecular Weight
- 38255.675 Da
References
- UniProt [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Catalytic activity
- General Function
- Zinc ion binding
- Specific Function
- Hydroxylates HIF-1 alpha at 'Asp-803' in the C-terminal transactivation domain (CAD). Functions as an oxygen sensor and, under normoxic conditions, the hydroxylation prevents interaction of HIF-1 w...
- Gene Name
- HIF1AN
- Uniprot ID
- Q9NWT6
- Uniprot Name
- Hypoxia-inducible factor 1-alpha inhibitor
- Molecular Weight
- 40285.25 Da
References
Drug created on November 30, 2015 19:10 / Updated on January 09, 2021 18:41